A Phase IB/IIA Study of the Saftey and Activity of Intravenous Isophosporamide Mustard (ZIO-201) in Patients With Advanced Sarcoma
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
toxicities
6 months
Yes
Jonathan Lewis, MD, PhD
Study Director
ZIOPHARM Oncology, Inc
United States: Food and Drug Administration
IPM2001
NCT00439686
February 2006
March 2008
Name | Location |
---|---|
Fountain Valley, California 92708 | |
Flint, Michigan 48532 |